Follitropin alfa is a Recombinant Protein owned by Merck, and is involved in 30 clinical trials, of which 29 were completed, and 1 is ongoing.

Follitropin beta is a glycoprotein hormone consisting of alpha and beta subunits made with number of aminoacids. This protein mainly binds to the receptors of the follicle stimulating hormone in female patients, thereby inducing the metabolic regulating pathways like phosphorylation, activation of the Phosphatidylinositol-3-kinase and the Akt signaling pathway. This process leads to an increase in the amount of hormone. Follitropin beta stimulates spermatogenesis in male patients.

The revenue for Follitropin alfa is expected to reach a total of $18.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Follitropin alfa NPV Report.

Follitropin alfa is currently owned by Merck.

Follitropin alfa Overview

Follitropin alfa (Gonal F / Ovidrel) is a recombinant human follicle stimulating hormone (r-hFSH) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. It is formulated in the form of injection solution and injection lyophilized powder solution, prefilled syringes for subcutaneous route and intramuscular route of administration. It is indicated to improve the multiple follicles in ovulatory patients, who are participating in an Assisted Reproductive Technology (ART) program in women. It is also used for the induction of ovulation and pregnancy in anovulatory infertile female patients, stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies. Gonal-F in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In men it is indicated for the induction of spermatogenesis with primary and secondary hypogonadotropic hypogonadism, and also indicated for controlled ovarian stimulation in assisted reproduction.

Merck Overview

Merck, a subsidiary of E. Merck KG, is a science and technology company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.

The company reported revenues of (Euro) EUR19,687 million for the fiscal year ended December 2021 (FY2021), an increase of 12.3% over FY2020. In FY2021, the company’s operating margin was 21.2%, compared to an operating margin of 17% in FY2020. In FY2021, the company recorded a net margin of 15.5%, compared to a net margin of 11.3% in FY2020. The company reported revenues of EUR5,806 million for the third quarter ended September 2022, an increase of 4.3% over the previous quarter.

Quick View – Follitropin alfa

Report Segments
  • Innovator (NME)
Drug Name
  • Follitropin alfa
Administration Pathway
  • Intramuscular
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Male Health
  • Women’s Health
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.